A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
NCT05511363 · Phase 3 · Recruiting
PHASEPhase 3
STATUSRecruiting
ENROLLMENT410
EST. COMPLETION2026-10-05
Conditions
Interventions
Study details
SPONSORKaruna Therapeutics, Inc., a Bristol Myers Squibb company
START DATE2022-08-23
Related company profiles
Primary source
Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.
Evidence & limits
Source: Open the source record
- Record identifier
- NCT05511363
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.
Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.
Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.